Patent intelligence · MX
MX 2013007491
GRANULATES COMPRISING ESLICARBAZEPINE ACETATE.
GRANULATES COMPRISING ESLICARBAZEPINE ACETATE.
Patent details — MX 2013007491
- Jurisdiction
- MX
- Status
- granted
- Grant date
- Aug 1, 2013
- Expiration
- Jul 27, 2033
- Applicant
- BIAL PORTELA & CA SA [PT]
- CPC classes
- A61K 9/ 16 A I, A61K 31/ 55 A I, A61K/3155, A61K/90053
Quick answer
MX 2013007491 (GRANULATES COMPRISING ESLICARBAZEPINE ACETATE.) is held by BIAL PORTELA & CA SA [PT]. Status: granted. Granted Aug 1, 2013. Expires Jul 27, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIAL PORTELA & CA SA [PT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 16 A I, A61K 31/ 55 A I, A61K/3155, A61K/90053, A61K/914, A61K/916
More from BIAL PORTELA & CA SA [PT]
Related pharmaceutical patents in our USPTO index.
-
WO 2022081033
OPICAPONE ET LÉVODOPA POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON
granted -
WO 2022025781
DISPERSION SOLIDE D'OPICAPONE
granted -
WO 2021182981
OPICAPONE MICRONISÉE
granted -
WO 2020246903
INHIBITEURS DE DOPAMINE-B-HYDROXYLASE
granted -
AU 2018379646
Dopamine-B-hydroxylase inhibitors
granted -
BR PI0923819
compostos farmacêuticos
granted -
EP 3515433
DIE BLUT-HIRN-SCHRANKE PASSIERENDE DOPAMIN-B-HYDROXYLASE-INHIBITOREN
granted -
US 2019008774
PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME
granted
Frequently asked questions
What is US patent 2013007491?
MX 2013007491 (GRANULATES COMPRISING ESLICARBAZEPINE ACETATE.) is held by BIAL PORTELA & CA SA [PT]. Status: granted. Granted Aug 1, 2013. Expires Jul 27, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns MX 2013007491?
BIAL PORTELA & CA SA [PT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.
When does MX 2013007491 expire?
Our index shows an expiration date of Jul 27, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.